



## Pixium Vision notified of threshold crossing following passive dilution

**Paris, 28 September 2020** – 7:00 am CET– Pixium Vision (**Euronext Growth Paris - FR0011950641**), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, has been informed by Bpifrance Investissement of a passive crossing of the threshold of 5% of the share capital, following the increase in the total number of shares and voting rights of the Company due to the conversion by L1 Capital of an amount of convertible debt into shares.

Bpifrance has not sold any shares and continues to support Pixium Vision and its strategy, through its active and continuing presence on its Board of Directors as well as through its holding of 6,150,344 shares since July 2020.

Bpifrance Investissement holds 2,134,094 shares since September 25<sup>th</sup>, 2020, representing 4,99% of the share capital at the date of this press release.

Number of Pixium Vision shares held	2015*	2016*	2017*	2018*	2019*	September 25th, 2020
Bpifrance Participations SA	1,030,000	1,030,000	1,030,000	1,416,250	1,416,250	4,016,250
Bpifrance Investissement (en sa qualité de société de gestion du Fonds Innobio)	1,599,335	1,599,335	1,599,335	2,134,094	2,134,094	2,134,094
Total EPIC Bpifrance	2,629,335	2,629,335	2,629,335	3,550,344	3,550,344	6,150,344
Total number of shares	12,739,795	13,233,081	14,887,056	22,156,363	24,368,221	42,753,073

\* : As of September 25th, 2020

## Contacts

### Pixium Vision

Guillaume Renondin  
Chief Financial Officer  
[investors@pixium-vision.com](mailto:investors@pixium-vision.com)  
+33 1 76 21 47 68

### Media relations

**LifeSci Advisors**  
Sophie Baumont  
[sophie@lifesciadvisors.com](mailto:sophie@lifesciadvisors.com)  
+33 6 27 74 74 49

### Investor relation

**LifeSci Advisors**  
Guillaume van Renterghem  
[gvanrenterghem@lifesciadvisors.com](mailto:gvanrenterghem@lifesciadvisors.com)  
+33 6 69 99 37 83

**Pixium Vision** is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: <http://www.pixium-vision.com/fr>

Follow us on [@PixiumVision](https://twitter.com/PixiumVision); [www.facebook.com/pixiumvision](https://www.facebook.com/pixiumvision)

Linked [in](https://www.linkedin.com/company/pixium-vision) [www.linkedin.com/company/pixium-vision](https://www.linkedin.com/company/pixium-vision)



Pixium Vision is listed on Euronext Growth Paris.  
Euronext ticker: ALPIX - ISIN: FR0011950641

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext GROWTH ALLSHARE index